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OBJECTIVE—Medium-chain fatty acids (MCFAs) have been
reported to be less obesogenic than long-chain fatty acids
(LCFAs); however, relatively little is known regarding their effect
on insulin action. Here, we examined the tissue-speciﬁc effects of
MCFAs on lipid metabolism and insulin action.
RESEARCH DESIGN AND METHODS—C57BL6/J mice and
Wistar rats were fed either a low-fat control diet or high-fat diets
rich in MCFAs or LCFAs for 4–5 weeks, and markers of mito-
chondrial oxidative capacity, lipid levels, and insulin action were
measured.
RESULTS—Mice fed the MCFA diet displayed reduced adiposity
and better glucose tolerance than LCFA-fed animals. In skeletal
muscle, triglyceride levels were increased by the LCFA diet (77%,
P  0.01) but remained at low-fat diet control levels in the
MCFA-fed animals. The LCFA diet increased (20–50%, P  0.05)
markers of mitochondrial metabolism in muscle compared with
low-fat diet–fed controls; however; the increase in oxidative
capacity was substantially greater in MCFA-fed animals (50–
140% versus low-fat–fed controls, P  0.01). The MCFA diet
induced a greater accumulation of liver triglycerides than the
LCFA diet, likely due to an upregulation of several lipogenic
enzymes. In rats, isocaloric feeding of MCFA or LCFA high-fat
diets induced hepatic insulin resistance to a similar degree;
however, insulin action was preserved at the level of low-fat
diet–fed controls in muscle and adipose from MCFA-fed animals.
CONCLUSIONS—MCFAs reduce adiposity and preserve insulin
action in muscle and adipose, despite inducing steatosis and
insulin resistance in the liver. Dietary supplementation with
MCFAs may therefore be beneﬁcial for preventing obesity and
peripheral insulin resistance. Diabetes 58:2547–2554, 2009
I
nsulin resistance, deﬁned as an impaired ability of
insulin to regulate carbohydrate and lipid metabo-
lism in target tissues, is one of the major metabolic
defects of obesity and type 2 diabetes. It is closely
linked with excess lipid deposition in nonadipose tissues,
particularly skeletal muscle and liver, and several mecha-
nisms have been proposed describing how lipid metabo-
lites antagonize insulin action (1,2). Although the precise
factors that cause inappropriate lipid accumulation are
still not completely resolved, a number of studies have
suggested that reduced mitochondrial capacity for lipid
oxidation, particularly in skeletal muscle, may lead to
partitioning of fatty acids into lipid storage pathways and
a subsequent deterioration in insulin sensitivity (1,3).
Given the close link between lipid accumulation and
reduced insulin action, one of the primary experimental
paradigms for investigating the etiology of insulin resis-
tance is high-fat feeding (e.g., 45–60% of calories) in
rodents. Many studies have demonstrated that consump-
tion of a diet high in long-chain fatty acids (LCFAs)
induces widespread insulin resistance in muscle, liver, and
adipose tissue of both rats and mice (4–7). Under these
conditions of excess LCFA availability, however, we (8)
and others (9) have demonstrated that mitochondrial
content and fatty acid oxidative capacity are actually
increased in muscle, suggesting that there is a compensa-
tory response to increase fatty acid utilization pathways,
which is insufﬁcient to prevent lipid overload and insulin
resistance. Indeed, we have recently shown that acute
overexpression of carnitine palmitoyltransferase (CPT)-1
in muscle increases fatty acid oxidative capacity above
that induced by high-fat feeding alone, and this partially
protects against lipid-induced insulin resistance (10).
While high-fat diets containing most classes of LCFAs
(e.g., saturated, monounsaturated, and omega-6) lead to
obesity and insulin resistance (4,6,11), an interesting
group of fatty acids that have been suggested to have
antiobesity potential are medium-chain (C8–12) fatty acids
(MCFAs) (12,13). Studies in humans and rodents have
shown that MCFAs induce higher energy expenditure and
fatty acid oxidation compared with LCFAs, and this is
associated with lower adipose mass (14–17). Compared
with LCFAs, however, less is known regarding the effect of
MCFAs on insulin sensitivity. In rats, high-fat diets rich in
MCFAs have been reported to be less deleterious for
glucose and insulin tolerance compared with LCFAs
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also suggested that MCFAs may not have detrimental
effects on insulin action (20,21). Whether speciﬁc tissues
are involved in the favorable effects of MCFAs on insulin
action is currently unclear, particularly as several studies
have shown that MCFAs induce hepatic steatosis (11,17),
which would be expected to have a negative impact on
insulin sensitivity in this tissue. Therefore, our aim in this
study was to investigate the tissue-speciﬁc effects of
high-fat diets containing MCFAs on lipid metabolism and
insulin action.
RESEARCH DESIGN AND METHODS
Eight-week-old male C57BL6/J mice and male Wistar rats were purchased
from the Animal Resources Centre (Perth, Australia). The animals were kept
in a temperature-controlled room (22  1°C) on a 12-h light/dark cycle with
free access to water. Mice and rats were fed ad libitum for 1 week on a
standard low-fat laboratory diet (low fat; 8% calories from fat, 21% calories
from protein, 71% calories from carbohydrate; Gordon’s Specialty Stock
Feeds, Yanderra, NSW, Australia) and were then randomly allocated to remain
on the low-fat diet or to receive a high-fat diet enriched with either LCFAs
from lard or MCFAs from hydrogenated coconut oil. The dietary fatty acid
composition was determined as described below and is presented in Table 1.
For mice, the high-fat diets were based on rodent diet no. D12451 (containing
45% of calories from fat) (Research Diets, New Brunswick, NJ), and animals
were fed ad libitum for a period of 5 weeks. For the rat studies, animals were
pair-fed LCFA and MCFA high-fat diets (59% of calories from fat) as previously
described (6). All experiments were carried out with the approval of the
Garvan Institute/St. Vincent’s Hospital Animal Experimentation Ethics Com-
mittee, following guidelines issued by the National Health and Medical
Research Council of Australia.
Determination of body composition and energy expenditure. Fat and
lean body mass were measured in mice using dual-energy X-ray absorptiom-
etry (Lunar PIXImus2 mouse densitometer; GE Healthcare) in accordance
with the manufacturer’s instructions. Oxygen consumption rate (VO2)o f
individual mice was measured using an eight-chamber indirect calorimeter
(Oxymax series; Columbus Instruments, Columbus, OH) as previously de-
scribed (8).
In vivo glucose metabolism. Glucose tolerance tests (2 g/kg glucose i.p.)
were performed in overnight-fasted mice. Blood samples were obtained from
the tail tip at the indicated times, and glucose levels were measured using a
glucometer (Accu-Check, Roche, NSW, Australia). For euglycemic-hyperinsu-
linemic clamps in rats (insulin infusion 0.25 units  kg
1  h
1), double jugular
cannulae were implanted 7 days prior to experiments, and animals (5 h fasted)
were studied over2hi nt h econscious state as previously described (22).
Fatty acid composition, triglycerides, and insulin levels. Lipids were
extracted from tissues and diets by standard methods (23). For tissue lipid
extracts, neutral lipids were separated from phospholipids by solid-phase
extraction on Waters Sep-Pak silica columns (Milford, MA). Lipid fractions
were transmethylated (24), and fatty acid methyl esters were separated by
gas-liquid chromatography on a Shimadzu 17A gas chromatograph (NSW,
Australia) with a Restek FAMEWAX capillary column (Bellefonte, PA).
Plasma, muscle, and liver triglyceride contents were determined using a
colorimetric assay kit (Triglycerides GPO-PAP; Roche Diagnostics, Indianap-
olis, IN) as previously described (22). Plasma insulin was determined by
radioimmunoassay using a rat-speciﬁc kit (Linco Research, St. Charles, MO).
Enzyme activity measurements. Muscle and liver samples were homoge-
nized 1:19 (wt/vol) in 50 mmol/l Tris-HCl, 1 mmol/l EDTA, and 0.1% Triton
X-100, pH 7.2, using a Polytron instrument (Kinematica, Littau-Lucerne,
Switzerland) and were subjected to three freeze-thaw cycles. Citrate synthase
(CS), -hydroxyacyl CoA dehydrogenase (HAD), and medium-chain acyl-CoA
dehydrogenase (MCAD) were determined at 30°C as described previously (8)
using a Spectra Max 250-microplate spectrophotometer (Molecular Devices,
Sunnyvale, CA).
Immunoblotting. Muscle and liver samples were resuspended in radioimmu-
noprecipitation buffer (65 mmol/l Tris [pH 7.4], 150 mmol/l NaCl, 1% nonidet
NP-40, 0.5% sodium deoxy-cholate, and 0.1% SDS), supplemented with pro-
tease and phosphatase inhibitors (10 g/ml phenylmethylsulfonyl ﬂuoride, 10
g/ml aprotinin and 10 g/ml leupeptin, 1 mmol/l Na3VO4, and 10 mmol/l NaF)
and solubilized for2ha t4°C. Equal amounts of tissue lysates (10–20 g
protein) were resolved by SDS-PAGE and immunoblotted with antibodies
against peroxisome proliferator–activated receptor (PPAR)- coactivator
(PGC)-1 from Chemicon International (Temecula, CA); muscle and liver
carnitine palmitoyltransferase-1 (CPT-1) from Alpha Diagnostic International
(San Antonio, TX); uncoupling protein 3 (UCP3) from Afﬁnity Bioreagents
(Golden, CO); fatty acid synthase (FAS), stearoyl-CoA desaturase (SCD-1),
and acetyl-CoA carboxylase (ACC) from Cell Signaling (Beverly, MA); cyto-
chrome oxidase (complex IV) subunit 1 from Invitrogen (Victoria, Australia);
and an antibody cocktail that recognizes several subunits of the mitochondrial
respiratory chain (MS601) from Mitosciences (Eugene, OR). Immunolabeled
bands were quantitated by densitometry.
Statistical analyses. Data are presented as means  SE. One-way ANOVA
with Fisher’s protected least-signiﬁcant difference post hoc test was used to
assess statistical signiﬁcance between groups. Differences at P  0.05 were
considered to be statistically signiﬁcant.
RESULTS
Body composition, glucose tolerance, and tissue tri-
glyceride levels in mice. At the completion of the 5-week
feeding regime, body mass was not different among mice
fed the low-fat, MCFA, and LCFA diets (Table 2). Whole-
body adiposity measured by dual-energy X-ray absorpti-
ometry scanning was not signiﬁcantly different between
MCFA-fed mice and low-fat–fed controls but was substan-
tially increased (P  0.01) in LCFA-fed mice (Table 2). The
reduced level of adipose accumulation in MCFA-fed mice
compared with LCFA-fed mice appeared to be primarily
due to an increased energy expenditure (VO2) in MCFA-fed
animals (MCFA 3.64  1.3 vs. LCFA 3.34  0.8 ml O2  g
1 
h
1, n  7, P  0.05), as although the caloric intake was
increased (P  0.01) in both fat-fed groups compared with
low-fat controls (11.5  0.5 kcal/day, n  6), no difference
was observed between the MCFA and LCFA diets (MCFA
14.2  0.1 vs. LCFA 14.6  0.4 kcal/day, n  5–6).
To determine the effect of the MCFA and LCFA diets on
whole-body glucose metabolism, we examined glucose
clearance during an intraperitoneal glucose tolerance test
(Fig. 1). Mice fed the LCFA diet displayed a substantial
impairment in glucose tolerance compared with low-fat–
TABLE 1
Fatty acid composition of the low-fat and high-fat diets
Fatty
acids
Low-fat
diet MCFAs LCFAs
8:0 0 7.3 0
10:0 0 5.7 0
12:0 0 36.7 0
14:0 0.6 16.5 1.3
16:0 13.1 9.8 24.6
18:0 4.0 10.5 15.3
18:1 (n-9) 38.7 3.0 32.1
18:2 (n-6) 31.7 9.8 21.7
18:3 (n-3) 6.7 0.3 0.9
Data are the percentage of total fatty acids. Fatty acid composition
was determined by gas chromatography.
TABLE 2
Body mass, fat pad mass, and tissue triglyceride levels in mice
Low-fat
diet MCFAs LCFAs
Body mass (g) 28.2  0.5 28.7  0.6 29.1  1.0
Fat mass (%) 14.7  0.6 17.3  1.7 25.6  1.9*†
Muscle triglycerides
(mol/g) 11.1  0.8 13.0  2.8 19.7  1.9*‡
Liver triglycerides
(mol/g) 8.5  0.7 49.7  4.4* 20.1  2.7*†
Data are means  SE for n  6–11 animals. Fat mass (%) was
determined by dual-energy X-ray absorptiometry scanning. *P  0.01
vs. low fat; †P  0.01 vs. MCFA; ‡P  0.05 vs. MCFA.
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in the glucose area under the curve (AUC). Animals fed the
MCFA diet exhibited a much milder impairment in glucose
tolerance (19% increase in area under the curve [P  0.05]
compared with low-fat–fed controls) (Fig. 1). Given the
established link between excess intracellular lipid and
insulin resistance (2), we examined tissue triglyceride
levels to determine whether the difference in glucose
tolerance in response to MCFAs and LCFAs may have
been linked to a differential effect of the high-fat diets on
liver and muscle lipid levels (Table 2). Muscle triglyceride
content was not different between low-fat–fed controls
and MCFA-fed mice but was signiﬁcantly elevated in
muscle from the LCFA-fed mice compared with both other
groups (Table 2). In contrast to this, liver triglycerides
were elevated by 	2.5-fold (P  0.01) in LCFA-fed animals
compared with low-fat–fed controls (Table 2), while
MCFA-fed animals displayed liver triglyceride levels that
were signiﬁcantly higher (P  0.01) than both low-fat–fed
controls and LCFA-fed mice.
Markers of mitochondrial metabolism and lipogenesis.
Mitochondria are a major site for lipid oxidation, and,
therefore, we examined several markers of mitochondrial
metabolism to determine whether the contrasting effects
of MCFAs and LCFAs on intracellular lipid levels may be
related to differences in fatty acid utilization. In skeletal
muscle, we observed a signiﬁcant upregulation (30–40%)
of citrate synthase, -hydroxyacyl CoA dehydrogenase,
and medium-chain acyl-CoA dehydrogenase activity in
LCFA-fed mice compared with low-fat–fed control animals
(Fig. 2). Interestingly, the MCFA diet induced a much
greater increase in muscle oxidative enzyme activity (90–
140% higher than low-fat–fed controls) (Fig. 2). We also
examined the protein expression of subunits of the mito-
chondrial respiratory chain, as well as CPT-1, UCP3, and
the transcriptional coactivator PGC-1. Similar to the
enzyme activities, increased expression of mitochondrial
proteins was observed in muscle of the LCFA-fed mice
compared with low-fat–fed controls, with a substantially
greater increase seen in the protein levels of respiratory
chain subunits, CPT-1, and UCP3 in MCFA-fed animals
(Fig. 3). Collectively, these ﬁndings suggest a more potent
stimulation of mitochondrial biogenic pathways in MCFA-
fed mice compared with the LCFA-fed animals; however,
this difference was not due to greater PGC-1 expression,
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FIG. 1. Glucose tolerance test in overnight-fasted low-fat (LF) (F), MCFA (E)-, and LCFA (u)-fed mice. A: Blood glucose levels after an
intraperitoneal glucose load (2 g/kg). B: Incremental areas under the curve as an indicator of glucose clearance. Data represent the means  SE
of 5–11 mice. *P < 0.01 vs. low fat; †P < 0.01 vs. low fat and MCFAs.
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FIG. 2. Oxidative enzyme activity in skeletal muscle and liver from mice fed the low-fat (LF) (f), MCFA (), and LCFA (1) diets. Data represent
the means  SE of 5–6 mice. *P < 0.01 vs. low fat and LCFAs; †P < 0.01 vs. low fat.
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(Fig. 3).
In liver, we observed no difference in the activity of
citrate synthase, -hydroxyacyl CoA dehydrogenase, or
medium-chain acyl-CoA dehydrogenase in either the
MCFA or LCFA group compared with low-fat–fed controls
(Fig. 2). There was no difference between the three dietary
groups in the expression of CPT-1 or subunits from
complex III and complex V of the respiratory chain;
however, LCFA-fed animals displayed a signiﬁcant reduc-
tion in the expression of subunits from complex II and
complex IV (Fig. 3). As there was marked hepatic steatosis
in MCFA-fed mice, without a consistent decrease in mark-
ers of fatty acid oxidative capacity, we also examined the
protein expression of several enzymes involved in lipogen-
esis to determine whether increased ﬂux through lipogenic
pathways may be underpinning the elevated triglyceride
accumulation in these animals. This appeared to be the
case, as compared with low-fat–fed controls, MCFA-fed
mice exhibited a 2.4-, 2.5-, and 12-fold increase (P  0.01,
n  6), respectively, in the protein expression of FAS,
ACC, and SCD-1, while relative to low-fat–fed controls,
LCFA-fed mice displayed a 43% increase (P  0.05, n  6)
in FAS expression, with no difference observed for ACC or
SCD-1 (Fig. 4).
Body composition and insulin action in rats. Overall,
our studies in mice showed that MCFAs have differential
effects on lipid metabolism in liver and muscle, and to
investigate the tissue-speciﬁc effect of MCFAs on insulin
action, we conducted hyperinsulinemic-euglycemic
clamps in rats pair-fed MCFA and LCFA high-fat diets.
Following 4 weeks of isocaloric high-fat feeding, rats fed
the MCFA diet displayed reduced body weight and lower
adiposity compared with the LCFA-fed animals (Table 3).
Plasma glucose, insulin, and triglyceride levels were sig-
niﬁcantly elevated in the LCFA-fed animals compared with
the low-fat–fed controls, while MCFA-fed rats displayed
only minor elevations in insulin and triglyceride levels
(Table 3). Similar to the pattern we observed in the mice,
muscle triglyceride levels were not different between
animals fed the low-fat and MCFA diets but were in-
creased in the LCFA-fed rats (Table 3). Liver triglyceride
LF MCFA LCFA
LF MCFA LCFA
Muscle
PGC-1α
CPT-1
UCP3
Complex II
Complex III
Complex IV
Complex V
change vs. LF
MCFA LCFA
↑ 27% *
↑ 44% †
↑ 53% †
↑ 57% †
↑ 65% *
↑ 47% *
↑ 80% †
↑ 2%  
↑ 1%
↑ 1%  
↓ 7% 
↑ 4%
CPT-1
Complex II
Complex III
Complex IV
Complex V
Liver
↑ 23% *
↑ 24% *
↑ 33% †
↓ 7% §
↑ 20% *  §
↑ 34% *  ‡
↑ 46% *  ‡
↓ 7%
↓ 37% †§
↑ 2%
↓ 33% 
↓ 1% 
†  §
FIG. 3. Immunoblots for markers of mitochondrial metabolism and biogenesis in skeletal muscle and liver from mice fed the low-fat (LF), MCFA,
and LCFA diets. Equal amounts of muscle lysates (10–20 g protein) were resolved by SDS-PAGE and immunoblotted with speciﬁc antibodies
for PGC-1, CPT-1, UCP3, and mitochondrial respiratory chain subunits. Densitometric analysis (relative to low-fat controls) for n  6 animals
is presented. *P < 0.05; †P < 0.01 vs. low fat; ‡P < 0.05; §P < 0.01 vs. MCFAs.
LF MCFA LCFA
FAS
ACC
SCD-1
FIG. 4. Immunoblots for enzymes involved in lipogenesis in liver from
mice fed the low-fat (LF), MCFA, and LCFA diets. Equal amounts of
liver lysates (10–20 g protein) were resolved by SDS-PAGE and
immunoblotted with speciﬁc antibodies for FAS, ACC, and SCD-1.
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with both the low-fat–fed controls and LCFA-fed rats
(Table 3).
Whole-body insulin sensitivity, measured as the glucose
infusion rate (GIR) during a hyperinsulinemic-euglycemic
clamp, was 44% (P  0.01) lower in the LCFA-fed rats
compared with low-fat–fed controls, while MCFA-fed ani-
mals displayed an 18% (P  0.01) reduction in GIR
compared with low-fat–fed controls (Table 4). The re-
duced GIR in LCFA-fed rats compared with low-fat–fed
controls was the result of both a reduced rate of insulin-
stimulated glucose disposal into peripheral tissues (Rd)
and a decreased suppression of hepatic glucose output
(HGO) (Table 4). In MCFA-fed rats, the effect of insulin to
suppress HGO was impaired to a similar degree to the
LCFA-fed rats, but strikingly, Rd was not different from
low-fat–fed controls. Skeletal muscle is the major periph-
eral tissue responsible for glucose disposal, and, accord-
ingly, we examined the uptake of
3H-2-deoxyglucose tracer
(Rg
) into red and white muscles during the clamp. Com-
pared with low-fat–fed controls, LCFA-fed rats exhibited a
reduction (25–40%, P  0.01) in Rg
 in both red and white
muscles (Table 4). Consistent with the results observed
for Rd, MCFA-fed animals exhibited similar (red muscle)
or even slightly increased (white muscle) Rg
 values com-
pared with low-fat–fed controls (Table 4). In the epididy-
mal adipose depot, we also observed a 45% reduction (P 
0.01) in Rg
 as a result of the LCFA diet, while the MCFA
diet preserved insulin action in this tissue (Table 4). Of
interest, we analyzed the fatty acid composition of liver,
muscle, and epididymal adipose tissue and found that in
MCFA-fed animals, MCFAs accounted for 	20% of the
total fatty acids in the neutral lipid fraction in muscle and
adipose (i.e., the two tissues that did not develop insulin
resistance) but 5% of the total fatty acids in liver, where
insulin action was diminished (data not shown). In low-
fat– and LCFA-fed animals, MCFAs accounted for 1% of
the total fatty acids in all tissues analyzed.
DISCUSSION
Previous studies examining the effect of different fatty
acids on insulin action have reported improved glucose
tolerance and insulin tolerance in rodents fed high-fat
diets rich in MCFAs compared with LCFAs (11,18,19). Our
current study reveals the tissues responsible for the favor-
able effect of MCFAs on whole-body glucose metabolism,
as well as a mechanistic basis for these effects. We have
made the intriguing observation that insulin action in
skeletal muscle and adipose tissue is preserved at the level
of low-fat–fed controls when animals consume a high-fat
diet rich in MCFAs. In muscle, the lack of induction of
insulin resistance with MCFA high-fat feeding is associ-
ated with a substantial increase in mitochondrial oxidative
capacity, which is sufﬁcient to prevent lipid accumulation
in this tissue. However, the liver of MCFA-fed animals
accumulated greater amounts of triglycerides, likely due
to upregulation of lipogenic pathways, and as such, he-
patic insulin action was reduced after MCFA high-fat
feeding.
It is likely that our ﬁndings have clinical relevance, as
several studies have suggested that MCFAs may be bene-
ﬁcial for insulin action in humans. Eckel et al. (20) showed
in a small (n  3) cohort of subjects with type 2 diabetes
that acute treatment with MCFAs (40% fat for 5 days)
resulted in a beneﬁcial effect on insulin-stimulated glucose
disposal, without consistent effects on insulin-mediated
suppression of HGO. Furthermore, a 3-month trial in
patients with type 2 diabetes reported improved homeo-
static model assessment of insulin resistance in subjects
consuming MCFAs compared with LCFAs (21). The above
human studies and those in rodents (11,18,19) indicate
that MCFAs do not induce insulin resistance to the same
degree as LCFAs; however, they have provided limited
information regarding the tissue-speciﬁc effects of MCFAs
on insulin action in vivo and/or a mechanism for any
observed beneﬁcial effects. Our current study clearly
shows that MCFAs do not induce insulin resistance in
either muscle and adipose tissue, and given the fact that
muscle is the major tissue for insulin-stimulated glucose
disposal (25), the reported favorable effects of MCFAs on
whole-body glucose metabolism (11,18,20,21) are probably
related to changes in insulin action in muscle. It is worth
noting, however, that the daily caloric intake in MCFA-fed
mice was 	25% higher than in low-fat–fed controls, and
whether with more prolonged high-fat feeding this ele-
vated energy intake would eventually lead to some meta-
bolic dysfunction in muscle and adipose tissue remains to
be determined.
The strong association between lipid accumulation and
insulin resistance is well documented (1,2,6), and our
TABLE 3
Body mass, fat pad mass, circulating parameters, and tissue
triglyceride levels in rats
Low-fat
diet MCFAs LCFAs
Body mass (g) 349  7 337  6 387  5*†
Epididymal fat (%) 1.0  0.1 1.3  0.1* 1.6  0.05*†
Retroperitoneal fat (%) 1.0  0.1 1.3  0.1 2.1  0.2*†
Lumbar fat (%) 1.5  0.1 1.5  0.1 2.2  0.1*†
Plasma glucose
(mmol/l) 7.2  0.2 7.5  0.2 8.1  0.2‡
Plasma insulin (mU/l) 24  23 1  36 6  5*†
Plasma triglycerides
(mmol/l) 0.8  0.1 0.9  0.0 1.1  0.2‡
Muscle triglycerides
(mol/g) 1.7  0.1 1.9  0.2 2.9  0.3*†
Liver triglycerides
(mol/g) 4.8  0.3 18.4  0.9* 14.4  2.1*†
Data are means  SE for n  5–9 animals. Fat pad weights are
expressed as a percentage of body mass. *P  0.01 vs. low fat; †P 
0.01 vs. MCFAs; ‡P  0.05 vs. low fat.
TABLE 4
Metabolic parameters from hyperinsulinemic-euglycemic clamps
in rats
Low-fat
diet MCFAs LCFAs
GIR (mg  kg
1  min
1) 38.4  1.6 31.4  1.3* 21.5  1.6*†
Rd (mg  kg
1  min
1) 36.9  1.3 34.3  1.1 25.9  1.9*†
HGO (mg  kg
1  min
1) 1.5  0.63 3.0  1.1* 4.3  0.4*†
Rg´ (red quadriceps) 29.4  2.0 26.5  1.8 16.9  2.7*†
Rg´ (red gastrocnemius) 29.7  2.8 26.8  1.4 17.6  0.8*†
Rg´ (white gastrocnemius) 7.1  0.6 9.0  0.6* 5.4  0.4*†
Rg´ (epididymal fat) 1.8  0.2 2.2  0.2 1.0  0.1*†
Data are means  SE for n  5–7 animals. Plasma levels of glucose
and insulin were similar for all groups during the clamp (data not
shown). *P  0.01 vs. low fat; †P  0.01 vs. MCFA. Rg´, insulin-
stimulated
3H-2-deoxyglucose uptake in skeletal muscle or adipose
tissue during the clamp (mol  100 g
1  min
1).
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muscle and concurrently preserve insulin action in this
tissue strongly support the above link. We and others have
reported that under conditions of increased lipid availabil-
ity, either through high-fat feeding (with LCFAs), acute
lipid infusions, or muscle-speciﬁc overexpression of li-
poprotein lipase, mitochondrial content and fatty acid
oxidative capacity are upregulated in muscle (8,9,26,27).
Such a response likely represents an attempt of the muscle
to cope with additional fatty acid substrates; however, the
fact that lipids still accumulate in muscle in animals under
these conditions suggests that the compensatory upregu-
lation of oxidative pathways is unable to deal with the
elevated uptake of LCFAs that is observed with such
manipulations (26,28). In comparison with LCFAs, how-
ever, we have shown that MCFAs induce a substantially
greater upregulation of mitochondrial oxidative capacity
in muscle, and this appears to be at a sufﬁcient level to
prevent the deleterious effects of lipid oversupply on
insulin action in this tissue.
The underlying molecular mechanism by which MCFAs
induce a more potent upregulation of mitochondrial biogen-
esis in muscle than LCFAs is currently unclear. We observed
a substantial accumulation of MCFAs in the neutral lipid
fraction of muscle from MCFA-fed animals, and one major
pathway through which fatty acids inﬂuence substrate me-
tabolism in muscle is via activation of PPAR, particularly
PPAR. These transcription factors, when activated by fatty
acids or other ligands, control genes involved in oxidative
and fatty acid metabolism (29). Several studies (30,31) have
shown, however, that MCFAs have low binding afﬁnity for
PPARs, suggesting that a direct effect of MCFAs on PPAR-
dependent transcription is unlikely responsible for the in-
crease in mitochondrial biogenesis. PPARs can also be
activated via interaction with the transcriptional coactivator
PGC-1, which is considered a master controller of mito-
chondrial biogenesis in muscle. We observed similar upregu-
lation of PGC-1 content in muscle with both the MCFA and
LCFA diets. However, posttranslational modiﬁcation (e.g.,
acetylation) of PGC-1 is known to regulate its activity (32),
and whether MCFAs speciﬁcally affect this pathway or inﬂu-
ence the activity of other transcription factors is currently
unknown.
In addition to oxidative metabolism, there are a number
of other pathways that inﬂuence lipid deposition in tis-
sues, including lipid uptake from the circulation and, for
tissues such as the liver, the rate of de novo lipogenesis.
With regard to these factors, MCFAs differ from LCFAs in
a number of important ways. MCFAs are more readily
absorbed into the bloodstream, and, therefore, a greater
proportion of these fatty acids reach the liver through the
portal vein (33). MCFAs can also enter the mitochondrion
for oxidation via CPT-1–independent mechanisms (34).
These unusual physical properties are thought to largely
explain the increase in energy expenditure and decreased
adiposity observed with MCFA-rich diets (i.e., due to
enhanced hepatic fatty acid oxidation), particularly in the
postprandial period (13). Our novel ﬁnding of a very
potent upregulation of mitochondrial content in muscle by
MCFAs suggests that enhanced ﬂux of substrates through
oxidative metabolism in muscle may also contribute to
MCFA-induced changes in energy expenditure and adipos-
ity, as well as improved muscle insulin action (current
study and 13–15).
The other tissue in which MCFAs were less deleterious
than LCFAs for insulin action was adipose tissue. Small
adipocytes are more insulin-sensitive than large adipo-
cytes (35,36), and previous studies (16,37) have demon-
strated that adipocyte size is reduced with MCFA diets,
potentially due to a reduction in adipogenic gene expres-
sion (18). It is likely that the preserved insulin sensitivity
we observed in adipose following MCFA high-fat feeding is
simply a consequence of reduced adipocyte size, although
given the fact that MCFAs accumulate signiﬁcantly in
adipose tissue following MCFA high-fat feeding (current
study and 18), we cannot rule out a more direct effect of
MCFAs on adipocyte function that may be beneﬁcial for
insulin action. Furthermore, as adipose tissue secretes a
number of adipokines that affect carbohydrate and lipid
metabolism in other tissues, it remains to be determined if
MCFA-induced changes in adipokine proﬁle (19) partly
contribute to the changes in mitochondrial content and
insulin action observed in skeletal muscle with the MCFA
high-fat diet.
Despite the favorable effects of MCFAs on muscle and
adipose metabolism, another important ﬁnding was that
MCFAs robustly induced insulin resistance in liver and
caused a greater degree of hepatic steatosis than LCFAs in
both mice and rats. This elevation in liver triglyceride
levels did not appear to be due to a decreased capacity for
lipid oxidation, as we observed generally similar levels of
mitochondrial enzyme activity and protein expression in
the different dietary groups. As mentioned above, the entry
of MCFAs into mitochondria is less dependent on CPT-1
than LCFAs, and a consequence of accelerated -oxidation
is an excess production of acetyl-CoA. Much of this
acetyl-CoA is converted into ketone bodies, which have
been reported to be elevated in MCFA-fed animals (17,38).
Acetyl-CoA is also a substrate for de novo lipogenesis, and,
in line with other reports (39,40), we observed a substan-
tial upregulation of lipogenic enzymes in liver from the
MCFA-fed mice, presumably to deal with the excess
acetyl-CoA, and this is likely a major contributor to the
increased triglyceride levels in these animals. Consistent
with this, we only observed a small proportion of MCFAs
in the neutral lipid fraction of liver from MCFA-fed ani-
mals, suggesting metabolism of these fatty acids through
lipogenic pathways.
There is controversy in the literature regarding the
effects of MCFAs on liver triglycerides. In rodents, a
number of studies (11,17) have reported increased liver
triglyceride levels with MCFA feeding, while others (16)
show no difference between high-fat diets containing
MCFAs or LCFAs. Interestingly, one recent study (41) in
rats suggested that liver triglyceride content is signiﬁ-
cantly lower with a diet containing only MCFAs compared
with LCFAs, but this effect was diminished in the presence
of LCFAs. In humans, a number of studies have reported
that MCFAs do not have adverse effects on liver lipid levels
(42,43); however, inconsistent ﬁndings have been reported
regarding the effect of MCFA on circulating lipid parame-
ters (21,44,45). It is possible that methodological differ-
ences may underlie many of these seemingly disparate
ﬁndings, such as the dietary fat content and composition,
the length of dietary intervention, and the composition of
other constituents of the diet (e.g., carbohydrates and
protein).
In summary, our study shows that high-fat diets contain-
ing MCFAs have divergent effects on tissue-speciﬁc insulin
sensitivity, inducing insulin resistance to a similar degree
as LCFAs in liver while preserving insulin action at the
level of low-fat–fed controls in muscle and adipose tissue.
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associated with a potent stimulation of mitochondrial
biogenesis, which appears to be sufﬁcient to prevent lipid
accumulation in this tissue. Given that the total amount of
dietary fat used in the current studies is relatively high
(i.e., 45–60% of energy), it will be important to determine
in future studies the amount of dietary MCFAs (both in
absolute terms and relative to dietary LCFAs) required for
beneﬁcial effects on energy metabolism and insulin action
and whether this amount of dietary MCFAs avoids liver
lipid accumulation. In this regard, some human studies
(21,46,47) have reported positive effects on energy expen-
diture and body composition with relatively low dietary
doses of MCFAs. Additionally, as some antidiabetes ther-
apies (e.g., metformin) are known to exert the majority of
their insulin-sensitizing effects via their actions in the liver
(48), it will be of interest to determine whether MCFA
supplementation in conjunction with such agents results
in beneﬁcial effects on insulin action in multiple insulin
target tissues.
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